Abstract Objective To study the clinical and laboratory characteristics of juvenile myelomonocytic leukemia (JMML). Methods The clinical characteristics and laboratory results were retrospectively analyzed in 10 children with newly diagnosed JMML. They were compared with those of 28 children with myelodysplastic syndrome (MDS) and 44 children with chronic myeloid leukemia (CML). Results Compared with the children with CML or MDS, the children with JMML had significantly higher rates of skin rashes, ecchymosis, and lymphadenectasis, a significantly lower serum cholinesterase (ChE) level, and a significantly higher fetal hemoglobin level (P < 0.05). The white blood cell count of children with JMML was significantly higher than that of children with MDS, but significantly lower than that of children with CML (P < 0.05). In addition, the myeloid/erythroid ratio and rate of dyshaematopoiesis were significantly lower in children with JMML than those in children with CML or MDS. The children with JMML had a significantly higher expression of mature monocyte marker CD14 than those with CML or MDS (P < 0.05). The levels of myeloid markers CD33, CD11b, CD13, and CD15 in children with JMML were significantly higher than those in children with MDS, but significantly lower than those in children with CML (P < 0.05). The levels of CD2 and CD7 in children with JMML were higher than those in children with CML, but lower than those in children with MDS (P < 0.05). Conclusions Skin rashes, ecchymosis, lymphadenectasis, and ChE reduction are more common in children with JMML than in those with CML or MDS, while dyshaematopoiesis is less common. In addition, CD14 level increases significantly in children with JMML.
Hasegawa D, Manabe A. Myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML)[M]//Ishii E. Hematological Disorders in Children. Singapore:Springer Singapore, 2017:87-108.
[2]
Satwani P, Kahn J, Dvorak CC. Juvenile myelomonocytic leukemia[J]. Pediatr Clin North Am, 2015, 62(1):95-106.
[3]
Masonsuares H, Toledo D, Gekas J, et al. Juvenile myelomonocytic leukemia-associated variants are associated with neonatal lethal Noonan syndrome[J]. Eur J Hum Genet, 2017, 25(4):509-511.
[4]
Hyjek E, Vardiman JW. Myelodysplastic/myeloproliferative neoplasms[M]//Jaffe ES, Harris NL, Vardiman JW, et al. Hematopathology. Philadelphia, Saunders, 2011:751-755.
[5]
Chan RJ, Cooper T, Kratz CP, et al. Juvenile myelomonocytic leukemia:a report from the 2nd International JMML Symposium[J]. Leuk Res, 2009, 33(3):355-362.
[6]
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20):2391-2405.
[7]
Niemeyer C M,Arico M,Basso G,et al.Chronic myelomonocytic leukemia in childhood:a retrospective analysis of 110 cases. European working group on myelodysplastic syndromes in childhood (EWOG-MDS)[J]. Blood, 1997, 89(10):3534-3543.
[8]
Harada H. Guest Editorial:Understanding of MPN and MDS/MPN based on molecular pathogenesis and clinical aspects[J]. Int J Hemato, 2017, 105(6):709-710.
[9]
Stieglitz E, Taylor-Weiner AN, Chang TY, et al. The genomic landscape of juvenile myelomonocytic leukemia[J]. Nat Genet, 2015, 47(11):1326-1333.
[10]
do Carmo GM, Crivellenti LZ, Bottari NB, et al. Butyrylcholinesterase as a marker of inflammation and liver injury in the acute and subclinical phases of canine ehrlichiosis[J]. Comp Immunol Microb Infect Dis, 2015, 43:16-21.
[11]
Yoshiba M, Sekiyama KK, Inoue K, et al. Accurate prediction of fulminant hepatic failure in severe acute viral hepatitis:multicenter study[J]. J Gastroenterol, 2002, 37(11):916-921.
[12]
Ramachandran J, Sajith KG, Priya S, et al. Serum cholinesterase is an excellent biomarker of cirrhosis[J]. Tro Gastroenterol, 2014, 35(1):15-20.
[13]
Prabhu K, Naik D, Ray S, et al. Significance of serum butyrylcholinesterase levels in oral cancer[J]. Australas Med J, 2011, 4(7):374-378.
[14]
Coulter DW, Boettner AD, Kortylewicz ZP, et al. Butyrylcholinesterase as a blood biomarker in neuroblastoma[J]. J Pediatr Hematol Oncol, 2017, 39(4):272-281.
[15]
Koie T, Ohyama C, Yamamoto H, et al. Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy[J]. Urol Oncol, 2014, 32(6):820-825.
[16]
Mitsunaga S, Kinoshita T, Hasebe T, et al. Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion[J]. Pancreas, 2008, 36(3):241-248.
[17]
Reis-Alves SC, Traina F, Harada G, et al. Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores[J]. PLoS One, 2013, 8(12):e81048.
[18]
Della Porta MG, Picone C. Diagnostic utility of flow cytometry in myelodysplastic syndromes[J]. Mediterr J Hematol Infect Dis, 2017, 9(1):e2017017.
[19]
Shen Q, Ouyang J, Tang G, et al. Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response[J]. Eur J Haematol, 2015, 95(2):168-176.
